Stock listing

NASDAQ:PALI Palisade Bio, Inc. Stock

Home listing (NASDAQ) of Palisade Bio, Inc.

Follow Palisade Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PALI

$0.84 USD -0.10 (-10.8%)

Close on Nov 20, 2026

Past year -64.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.838 – $0.96 USDNov 20, 2026
Volume
3.19M sharesNov 20, 2026
Market cap
$150.6M USDAt the close on Nov 20, 2026 · price × 179.3M shares outstanding
52-week range
$0.838 – $2.86 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.61M USDMedian day 2.07M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Palisade Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PALI · Home$0.84 USD-0.102 (-10.8%)3,190,610$0.911$0.96$0.838$0.942Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PALI · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.84-0.102-10.8%$0.911$0.96$0.8383,190,610
$0.942-0.068-6.7%$1.00$1.005$0.9395,304,544
$1.01-0.02-1.9%$1.00$1.036$0.991,952,612
$1.03-0.09-8.0%$1.09$1.111$1.011,664,788
$1.12-0.02-1.8%$1.15$1.15$1.081,458,544
$1.14-0.03-2.6%$1.16$1.175$1.13985,370
$1.17+0.04+3.5%$1.11$1.185$1.112,964,152
$1.13-0.06-5.0%$1.18$1.20$1.111,618,816
$1.19+0.06+5.3%$1.16$1.23$1.1451,407,053
$1.13-0.03-2.6%$1.14$1.18$1.102,029,638
$1.16-0.09-7.2%$1.22$1.225$1.102,591,414
$1.25+0.02+1.6%$1.26$1.30$1.212,014,098
$1.23+0.11+9.8%$1.14$1.245$1.1318,627,703
$1.12-0.04-3.4%$1.20$1.20$1.083,065,248
$1.16-0.03-2.5%$1.18$1.20$1.123,090,528
$1.190.000.0%$1.20$1.25$1.153,499,620
$1.19-0.01-0.8%$1.22$1.22$1.1015,113,518
$1.20-0.03-2.4%$1.22$1.255$1.176,011,066
$1.23-0.10-7.5%$1.33$1.34$1.211,702,019
$1.33-0.02-1.5%$1.35$1.37$1.281,153,900
$1.35-0.05-3.6%$1.38$1.41$1.351,111,800
$1.40-0.03-2.1%$1.44$1.46$1.391,432,800
$1.43+0.09+6.7%$1.39$1.48$1.342,817,400
$1.34-0.07-5.0%$1.41$1.46$1.321,834,400
$1.41-0.13-8.4%$1.55$1.56$1.403,888,900
$1.54+0.06+4.1%$1.50$1.56$1.481,817,600
$1.48+0.01+0.7%$1.45$1.51$1.384,162,500
$1.47-0.12-7.5%$1.56$1.58$1.461,587,900
$1.59+0.05+3.2%$1.53$1.63$1.511,571,700
$1.54+0.09+6.2%$1.49$1.57$1.471,840,400
$1.45-0.03-2.0%$1.47$1.48$1.382,083,900
$1.48-0.01-0.7%$1.46$1.48$1.44825,200
$1.49+0.03+2.1%$1.51$1.55$1.471,972,700
$1.46+0.02+1.4%$1.44$1.48$1.411,595,700
$1.44+0.01+0.7%$1.46$1.48$1.431,993,500
$1.43+0.08+5.9%$1.39$1.46$1.372,644,700
$1.35-0.10-6.9%$1.44$1.46$1.324,765,200
$1.45-0.05-3.3%$1.54$1.55$1.422,164,000
$1.50+0.05+3.4%$1.45$1.53$1.438,683,300
$1.45-0.12-7.6%$1.57$1.59$1.455,780,700
$1.57-0.03-1.9%$1.60$1.60$1.503,257,200
$1.60-0.09-5.3%$1.69$1.70$1.592,941,400
$1.690.000.0%$1.71$1.71$1.604,982,600
$1.69+0.10+6.3%$1.64$1.69$1.603,574,200
$1.59-0.11-6.5%$1.68$1.72$1.596,869,400
$1.70+0.01+0.6%$1.75$1.76$1.655,396,600
$1.69-0.33-16.3%$2.04$2.04$1.678,407,600
$2.02-0.03-1.5%$2.05$2.06$1.964,489,400
$2.05-0.01-0.5%$2.05$2.11$2.021,813,500
$2.06+0.05+2.5%$2.05$2.10$2.022,399,400
$2.01-0.04-2.0%$2.05$2.11$2.012,646,400
$2.05-0.15-6.8%$2.17$2.21$2.052,774,700
$2.20+0.11+5.3%$2.09$2.24$2.083,529,800
$2.09+0.04+2.0%$2.03$2.12$2.001,755,300
$2.05+0.06+3.0%$2.01$2.05$1.971,086,600
$1.99+0.03+1.5%$1.96$2.01$1.95730,700
$1.96+0.01+0.5%$1.96$1.98$1.92879,400
$1.95-0.05-2.5%$2.02$2.02$1.931,645,100
$2.00-0.11-5.2%$2.10$2.11$1.992,127,100
$2.11-0.02-0.9%$2.12$2.16$2.10899,100
$2.13+0.06+2.9%$2.06$2.14$2.031,190,100
$2.07+0.06+3.0%$2.02$2.10$1.982,068,108
$2.01-0.09-4.3%$2.10$2.10$2.001,618,511
$2.10+0.04+1.9%$2.09$2.14$2.081,070,300
$2.06-0.10-4.6%$2.14$2.15$2.031,324,900

Splits

5 splits since 2017 · NASDAQ:PALI · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
1-for-50Consolidation
1-for-6Consolidation
1-for-20Consolidation
1-for-13Consolidation
Ticker
NASDAQ:PALI
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Palisade Bio, Inc. news

Palisade Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
31 in the last 12 months · 152 in all · newest Nov 10, 2026 · oldest 2021
Decks
45 decks · latest September 2025

Where Palisade Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PALI · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PALIBOATSUnited StatesUSD
gettex:7NS0gettexGermanyEUR
Frankfurt:7NS0FrankfurtGermanyEUR
Lang & Schwarz:A4098SLang & SchwarzGermanyEUR
Munich:7NS0MunichGermanyEUR

Valuation

EV/sales 73.9× against a median of 39.0×: 5th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$36.96M USD
P/E
Loss
EV/sales
73.9×
EV/EBITDA
Negative EBITDA
Price/book
1.3×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.41

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Palisade Bio, Inc. · NASDAQ:PALIUS$150.6MUS$36.96Mn/a73.9×n/a1.3×n/a0.0×1.41
BioVersys AG · SIX:BIOVUS$154.1MUS$97.45Mn/a102×n/a2.9×n/a0.5×n/a
InflaRx N.V. · NASDAQ:IFRXUS$153.3MUS$135.7Mn/a4,215×n/a19.5×n/a0.0×1.61
Polaris Group · TWSE:6550US$153.0MUS$154.8Mn/a75.1×n/a1.1×n/a0.5×n/a
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541US$152.0MUS$64.59Mn/a2.9×n/a1.6×−141.7%0.6×n/a
Saniona AB · OMXSTO:SANIONUS$151.6MUS$104.0M8.4×2.5×5.2×2.8×43.2%0.0×n/a
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
Median of the othersUS$151.0MUS$89.06M8.4×39.0×5.2×2.0×−155.7%0.1×1.60

Forecasts

7 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
8.90 USD · Analysts' mean
EPS, year to Dec 2026
-0.24 · 2 analysts
Revenue, year to Dec 2026
500K · 6 analysts

Team and board

Officers

OfficerRole
JD FinleyChief Executive Officer and Director
Mitch JonesPresident and Chief Medical Officer
Julien E. CapersGeneral Counsel & Corporate Secretary
Ramesh DonthamsettyHead of IR and Corporate Strategy
Adarsh PatelHead of Chemistry, Manufacturing and Controls (CMC)
Daniel J. LarkinsHead of Global Regulatory Affairs
Dawn LouroHead of Clinical Operations
James IzanecHead of Clinical Development
Joerg HeyerHead of Translational Science and Medicine
Ryker WillieHead of Finance and Corporate Controller

Board

DirectorRole
Donald A. WilliamsChairman of the Board
Binxian WeiDirector
Emil ChuangDirector
JD FinleyChief Executive Officer and Director
Jordan ZwickDirector
Robert BalteraDirector

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · After close+3.5%
Q2 2026Aug 10, 2026 · After close+1.9%
Q1 2026May 13, 2026−5.7%
Q4 2025Mar 25, 2026−2.0%
Q3 2025Nov 10, 2025 · After close+2.8%
Q2 2025Aug 11, 2025 · After close+1.4%
Q1 2025May 12, 2025 · After close−5.2%
Q4 2024Mar 25, 2025 · Before open−1.4%
Q3 2024Nov 12, 2024 · Before open−4.4%
Q2 2024Aug 12, 2024 · After close+1.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · After close+0.3%
Q4 2023Mar 26, 2024 · After close+8.1%
Q3 2023Nov 9, 2023 · After close+1.9%
Q2 2023Aug 10, 2023 · After close+2.9%
Q1 2023May 11, 2023 · After close−1.9%
Q4 2022Mar 22, 2023 · After close−2.9%
Q3 2022Nov 14, 2022 · Before open0.0%
Q2 2022Aug 15, 2022 · Before open−4.2%
Q1 2022May 13, 2022 · Before open+8.5%
Q4 2021Mar 17, 2022 · After close−12.0%

Open Events

Decks

DeckKindSlidesDate
STAR Annual Meeting 2025Conference18 slidesSeptember 2025
8th Anti-Fibrotic Drug Development Summit (November 2024)Conference17 slidesNovember 2024
Investor Presentation (April 2024)Investor deck25 slidesApril 2024
IBD Innovate 2024Conference27 slidesApril 2024
Investor Presentation (January 2024)Investor deck25 slidesJanuary 2024
Investor Presentation (November 2023)Investor deck26 slidesNov 7, 2023
Investor Presentation (February 2023)Investor deck24 slidesFebruary 2023
IPO Roadshow (July 2022)IPO roadshow34 slidesJul 25, 2022
Investor Presentation (May 2022)Investor deck46 slidesMay 3, 2022
SAGES 2022Conference24 slidesMar 16, 2022
All 45 decks
DeckKindSlidesDate
Investor Presentation (February 2022)Investor deck38 slidesFeb 24, 2022
Investor Presentation (January 2022)Investor deck39 slidesJan 11, 2022
Investor Presentation (October 2021)Investor deck39 slidesOct 28, 2021
Investor Presentation (September 2021)Investor deck30 slidesSep 13, 2021
Investor Presentation (June 2021)Investor deck37 slidesJun 1, 2021
Investor Presentation (April 2021)Investor deck37 slidesApr 28, 2021
Seneca Biopharma — Investor Presentation (February 2020)Investor deck14 slidesFeb 24, 2020
Neuralstem — Investor Presentation (November 2019)Investor deck25 slidesNov 4, 2019
Neuralstem — IPO Roadshow (July 2019)IPO roadshow24 slidesJul 22, 2019
Neuralstem — MGH CTNI Europe 2018Conference29 slidesJul 5, 2018
Neuralstem — Investor Presentation (June 2018)Investor deck25 slidesJun 8, 2018
Neuralstem — Investor Presentation (March 2018)Investor deck23 slidesMar 16, 2018
Neuralstem — Cell & Gene Therapy World (January 2018)Conference17 slidesJan 24, 2018
Neuralstem — Investor Presentation (January 2018)Investor deck28 slidesJan 9, 2018
Neuralstem — Neuroscience Innovation Forum 2018Conference18 slidesJan 9, 2018
Neuralstem — Technical Presentation (May 2017)Technical30 slidesMay 31, 2017
Neuralstem — Investor Presentation (April 2017)Investor deck25 slidesApr 19, 2017
Neuralstem — Investor Presentation (February 2017)Investor deck41 slidesFeb 27, 2017
Neuralstem — Investor Presentation (June 2016)Investor deck26 slidesJun 23, 2016
Neuralstem — Investor Presentation (June 2016)Investor deck20 slidesJun 10, 2016
Neuralstem — Investor Presentation (April 2016)Investor deck21 slidesApr 13, 2016
Neuralstem — 28th Annual Roth Conference 2016Conference19 slidesMar 16, 2016
Neuralstem — Investor Presentation (March 2016)Investor deck22 slidesMar 4, 2016
Neuralstem — Phacilitate Cell & Gene Therapy World 2016Conference31 slidesJan 27, 2016
Neuralstem — Biotech Showcase 2016Conference13 slidesJan 11, 2016
Neuralstem — Barclays Global Healthcare Conference 2015Conference23 slidesMar 12, 2015
Neuralstem — The 17th Annual BIO CEO & Investor Conference (February 2015)Conference17 slidesFeb 9, 2015
Neuralstem — Investor Presentation (September 2014)Investor deck16 slidesSep 11, 2014
Neuralstem — Investor Presentation (September 2013)Investor deck22 slidesSep 10, 2013
Neuralstem — Investor Presentation (May 2013)Investor deck29 slidesMay 23, 2013
Neuralstem — Investor Presentation (February 2013)Investor deck29 slidesFeb 15, 2013
Neuralstem — Investor Presentation (January 2013)Investor deck24 slidesJan 9, 2013
Neuralstem — Investor Presentation (August 2012)Investor deck30 slidesAug 3, 2012
Neuralstem — Investor Presentation (January 2012)Investor deck10 slidesJan 12, 2012
Neuralstem — Investor Presentation (September 2011)Investor deck15 slidesSep 13, 2011

Open Decks

Financings

RaiseDate
Strategic investment of equity
Announced: up to US$500,000
Buyers: Crohn’s & Colitis Foundation (IBD Ventures program) (strategic equity investment of up to $500,000)
Use of proceeds: Continued clinical and mechanistic development of PALI-2108 for fibrostenotic Crohn's disease and ulcerative colitis
Jan 7, 2026
Public offering of common stock (or common stock equivalents)
Closed: US$138M raised · US$0.7 a share · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Buyers: B Group Capital (led the offering); Columbia Threadneedle Investments (led the offering); Adage Capital Partners LP (significant participation); ADAR1 Capital Management (significant participation); Boxer Capital Management (significant participation); Coastlands Capital (significant participation); Deep Track Capital (significant participation); Janus Henderson Investors (significant participation); Octagon Capital (significant participation); Perceptive Advisors (significant participation); RA Capital Management (significant participation); Squadron Capital Management (significant participation)
Use of proceeds: To support the upcoming Phase 2 clinical development program for PALI-2108 in ulcerative colitis
Oct 2, 2025
Warrant exercise of existing warrants to purchase common stock
Announced: about US$3.9M · US$0.9047 a share · Warrants at US$0.9047 for 60 months · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Use of proceeds: Working capital and general corporate purposes
Jul 24, 2025
Public offering of class A Units and Class B Units (common stock or prefunded warrants with common warrants)
Announced: about US$5M · US$1.525 a unit · Warrants at US$1.4 for 60 months · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Use of proceeds: Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital
Dec 12, 2024

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00250.0K0013.5K15.4K260.0K260.0K16.2K
Cost of revenue3.00K3.00K4.00K167.0K168.0K146.0K-990.0K
Gross profit-3.00K-3.00K250.0K-167.0K-168.0K-146.0K15.4K1.25M260.0K16.2K
Research and development10.2M16.0M6.89M6.55M2.43M2.02M4.06M3.96M8.10M13.2M
Selling, general and administrative7.86M5.80M6.20M8.76M9.31M6.20M7.27M3.57M5.47M7.50M
Operating income-18.1M-14.9M-13.1M-15.7M-41.9M-9.30M-8.63M-8.26M-13.3M-20.6M
Depreciation and amortization3.00K3.00K4.00K3.00K2.00K3.00K143.9K185.8K289.2K337.5K
EBITDA-18.1M-14.9M-13.1M-15.7M-41.9M-9.29M-8.49M-8.07M-13.0M-20.3M
Interest expense10.0K12.0K15.0K13.0K2.40M235.0K8.92K7.70K159.1K1.14M
Income before tax-16.8M-14.4M-12.3M-14.3M-26.6M-10.3M-8.35M-4.92M-15.7M-21.1M
Income tax000001.00K289.0K3.34M-2.20M0
Net income-16.8M-14.4M-12.3M-14.3M-26.6M-10.3M-8.35M-4.92M-15.7M-21.1M
Earnings per share, basic-0.30-10.19-27.01-16.53-142.95-3.72-3.80-7.54-1.20-2.53
Earnings per share, diluted-0.30-10.19-27.01-16.53-169.74-3.72-3.80-7.54-1.20-2.53

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents133.4M9.82M12.4M12.4M10.5M713.0K5.11M5.79M6.67M15.2M
Short-term investments16.0K5.00M5.00M
Receivables00148.0K0059.0K21.1K294.1K312.8K10.5K
Inventory12.0K-1.44M-150.0K-2.23M
Current assets134.2M10.5M13.3M14.7M11.5M896.0K5.65M6.51M12.4M20.9M
Property, plant and equipment03.00K10.0K10.0K3.00K5.00K41.0K90.3K172.9K269.6K
Total assets134.3M10.9M14.1M15.8M12.5M3.02M6.58M7.68M13.9M22.6M
Accounts payable767.0K1.10M698.0K1.76M1.32M2.54M824.4K832.6K875.1K2.34M
Current liabilities4.64M3.24M2.59M3.01M2.50M8.08M1.22M1.05M1.51M7.33M
Long-term debt094.0K
Total debt71.0K169.0K369.0K404.0K87.0K1.14M288.5K5.04M3.71M
Total liabilities4.96M3.39M2.74M3.28M5.15M10.1M1.46M1.63M5.37M11.3M
Shareholders' equity129.4M7.49M11.3M12.5M7.37M-16.6M-8.33M6.05M8.52M11.3M
Shares outstanding159.4M2.77M618.1K2.94M284.8K2.77M3.87M910.3K15.2M11.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-10.8M-12.2M-11.1M-13.4M-14.8M-4.77M-7.26M-7.69M-13.4M-15.6M
Capital spending00-4.00K-10.0K0-6.00K-6.00K-1.71K-11.4K-98.1K
Free cash flow-10.8M-12.2M-11.1M-13.4M-14.8M-4.77M-7.26M-7.69M-13.4M-15.7M
Cash from investing0-4.00K-10.0K-54.0K-6.00K3.92M5.00M-94.0K2.36M
Cash from financing134.4M9.58M11.2M15.3M24.6M1.89M6.59M1.81M4.99M23.7M
Dividends paid-99.0K
Share buybacks19.0K11.0K17.0K-99.0K14.7M6.55M1.83M8.74M28.1M
Change in cash123.6M-2.61M49.0K1.89M9.78M-2.88M-672.2K-887.8K-8.52M10.5M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 19, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 10, 2026ResultsSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 9, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2026Big-stake noticeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 7, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 7, 2026Insider tradeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
8-K · Current reportAug 10, 2026ResultsSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
4 · Change in ownershipJul 10, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
144 · Notice of proposed saleJul 7, 2026Other filingsSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
4 · Change in ownershipJun 18, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 18, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 12, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Management or board changeSEC
S-8 · Registration statement for employee plansJun 10, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeMay 27, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMay 22, 2026Other filingsSEC
CORRESP · Letter to the SECMay 19, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 19, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
S-3 · Registration statementMay 12, 2026Offer documentSEC
8-K · Current reportMay 12, 2026ResultsSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
8-K · Current reportApr 2, 2026Current reportSEC
10-K · Annual reportMar 20, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
4 · Change in ownershipFeb 11, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 29, 2026Big-stake noticeSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 8, 2025Big-stake noticeSEC
8-K · Current reportDec 4, 2025Meeting outcomeSEC
S-8 · Registration statement for employee plansNov 12, 2025Offer documentSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
4/A · Change in ownership, amendedNov 6, 2025Insider tradeSEC
4/A · Change in ownership, amendedNov 6, 2025Insider tradeSEC
4/A · Change in ownership, amendedNov 6, 2025Insider tradeSEC
DEFA14A · Additional proxy materialNov 3, 2025Meeting noticeSEC
DEF 14A · Proxy statementOct 29, 2025Meeting noticeSEC
8-K · Current reportOct 22, 2025Management or board changeSEC
8-K · Current reportOct 20, 2025Meeting outcomeSEC
PRE 14A · Preliminary proxy statementOct 20, 2025Meeting noticeSEC
8-K · Current reportOct 16, 2025Current reportSEC
8-K · Current reportOct 9, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 9, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 9, 2025Big-stake noticeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 8, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 7, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialOct 7, 2025Meeting noticeSEC
424B4 · ProspectusOct 2, 2025Offer documentSEC
S-1MEF · Registration of more shares for the same offeringOct 1, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 1, 2025Other filingsSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
S-1 · Registration statementSep 29, 2025Offer documentSEC
8-K · Current reportSep 26, 2025Current reportSEC
8-K · Current reportSep 18, 2025Current reportSEC
DEF 14A · Proxy statementSep 15, 2025Meeting noticeSEC
ARS · Annual report to shareholdersSep 15, 2025Annual reportSEC
DEFA14A · Additional proxy materialSep 15, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 5, 2025Meeting noticeSEC
8-K · Current reportSep 5, 2025Management or board changeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
4 · Change in ownershipSep 5, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 29, 2025Other filingsSEC
CORRESP · Letter to the SECAug 26, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 21, 2025Other filingsSEC
DEF 14A · Proxy statementAug 18, 2025Meeting noticeSEC
S-3 · Registration statementAug 15, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
PRE 14A · Preliminary proxy statementAug 6, 2025Meeting noticeSEC
8-K · Current reportJul 24, 2025Material contractSEC
4 · Change in ownershipJul 22, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 17, 2025Insider tradeSEC
UPLOAD · Letter from the SECJul 14, 2025Other filingsSEC
8-K · Current reportJul 9, 2025Management or board changeSEC
DRS · Draft registration statementJul 2, 2025Offer documentSEC
RW · Request to withdraw a registrationJun 11, 2025Other filingsSEC
S-1 · Registration statementMay 27, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
DRS · Draft registration statementMay 5, 2025Offer documentSEC
8-K · Current reportMay 2, 2025Current reportSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
424B3 · ProspectusDec 17, 2024Offer documentSEC
424B3 · ProspectusDec 17, 2024Offer documentSEC
424B3 · ProspectusDec 17, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 17, 2024Other filingsSEC
8-K · Current reportDec 16, 2024Material contractSEC
424B5 · ProspectusDec 13, 2024Offer documentSEC
POS AM · Amendment to an effective registrationDec 13, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 13, 2024Other filingsSEC
CORRESP · Letter to the SECDec 12, 2024Other filingsSEC
CORRESP · Letter to the SECDec 12, 2024Other filingsSEC
CORRESP · Letter to the SECDec 11, 2024Other filingsSEC
CORRESP · Letter to the SECDec 11, 2024Other filingsSEC
CORRESP · Letter to the SECDec 10, 2024Other filingsSEC
CORRESP · Letter to the SECDec 10, 2024Other filingsSEC
S-1/A · Registration statement, amendedDec 9, 2024Offer documentSEC
S-1/A · Registration statement, amendedDec 5, 2024Offer documentSEC
FWP · Free writing prospectusNov 22, 2024Offer documentSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
S-1/A · Registration statement, amendedNov 21, 2024Offer documentSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
UPLOAD · Letter from the SECNov 4, 2024Other filingsSEC
S-1 · Registration statementOct 30, 2024Offer documentSEC
8-K · Current reportSep 27, 2024Material contractSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
8-K · Current reportJul 8, 2024Meeting outcomeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipJun 12, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 30, 2024Insider tradeSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
4 · Change in ownershipMay 28, 2024Insider tradeSEC
4 · Change in ownershipMay 22, 2024Insider tradeSEC
ARS · Annual report to shareholdersMay 22, 2024Annual reportSEC
DEFA14A · Additional proxy materialMay 22, 2024Meeting noticeSEC
DEF 14A · Proxy statementMay 22, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMay 20, 2024Other filingsSEC
424B3 · ProspectusMay 17, 2024Offer documentSEC
3 · Initial statement of ownershipMay 16, 2024Insider tradeSEC
CORRESP · Letter to the SECMay 15, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 14, 2024Other filingsSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 10, 2024Management or board changeSEC
DMay 10, 2024Other filingsSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
4 · Change in ownershipMay 8, 2024Insider tradeSEC
S-3 · Registration statementMay 8, 2024Offer documentSEC
8-K · Current reportMay 3, 2024Material contractSEC
8-K · Current reportApr 10, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveApr 8, 2024Other filingsSEC
424B3 · ProspectusApr 5, 2024Offer documentSEC
8-K · Current reportApr 5, 2024Current reportSEC
CORRESP · Letter to the SECApr 3, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 3, 2024Other filingsSEC
S-3 · Registration statementMar 29, 2024Offer documentSEC
S-8 · Registration statement for employee plansMar 29, 2024Offer documentSEC
8-K · Current reportMar 27, 2024ResultsSEC
10-K · Annual reportMar 26, 2024Annual reportSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
8-K · Current reportMar 6, 2024Management or board changeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Palisade Bio, Inc.’s releases · as of Nov 6, 2026

Common shares
179,277,820
Fully diluted
179,277,820

Fully diluted

LineSharesAs of
Common shares179,277,820Nov 6, 2026

Share count over time

CountShares
Nov 6, 2026179,277,820
Sep 30, 2026174,442,971

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Soleus Capital Management, L.P.15M8.4%US$20.2MSep 30, 2026
Ameriprise14.6M8.1%US$19.7MSep 30, 2026
B Group, Inc.11.4M6.4%US$15.4MSep 30, 2026
BlackRock11.1M6.2%US$15MSep 30, 2026
Janus Henderson10.7M6.0%US$14.4MSep 30, 2026
Vanguard10.5M5.9%US$14.2MSep 30, 2026
Octagon Capital Advisors LP10.3M5.7%US$13.9MSep 30, 2026
Perceptive Advisors LLC8.43M4.7%US$11.4MSep 30, 2026
Ra Capital Management, L.P.7.12M4.0%US$9.62MSep 30, 2026
Franklin Templeton6.07M3.4%US$7.59MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Point72 Asset Management, L.P.5.87M3.3%US$7.93MSep 30, 2026
Wellington5.41M3.0%US$7.3MSep 30, 2026
Boxer Capital Management, LLC4.8M2.7%US$6.48MSep 30, 2026
Adage Capital Partners Gp, L.L.C.4.5M2.5%US$6.08MSep 30, 2026
Geode Capital3.86M2.2%US$5.21MSep 30, 2026
Eversept Partners, LP3.47M1.9%US$4.69MSep 30, 2026
Federated Hermes, Inc.3.14M1.7%US$4.23MSep 30, 2026
Squadron Capital Management LLC3M1.7%US$4.05MSep 30, 2026
State Street2.93M1.6%US$3.96MSep 30, 2026
Goldman Sachs2.72M1.5%US$3.67MSep 30, 2026
Vestal Point Capital, LP2.5M1.4%US$3.38MSep 30, 2026
Sphera Funds Management LTD.2.46M1.4%US$3.33MSep 30, 2026
Silverarc Capital Management, LLC2.34M1.3%US$3.15MSep 30, 2026
abrdn2.28M1.3%US$3.07MSep 30, 2026
Propel Bio Management, LLC2.22M1.2%US$3MSep 30, 2026
Platinum Investment Management LTD2.18M1.2%US$2.95MSep 30, 2026
Los Angeles Capital Management LLC2.13M1.2%US$2.88MSep 30, 2026
Siren, L.L.C.2M1.1%US$2.7MSep 30, 2026
ADAR1 Capital Management, LLC1.54M0.86%US$2.08MSep 30, 2026
Northern Trust1.25M0.70%US$1.69MSep 30, 2026
HighVista Strategies LLC1.15M0.64%US$1.55MSep 30, 2026
UBS1.08M0.60%US$1.46MSep 30, 2026
Millennium917K0.51%US$1.24MSep 30, 2026
Creek Drive Management Group LLC680K0.38%US$918KSep 30, 2026
BIT Capital GmbH679K0.38%US$917KSep 30, 2026
Nuveen525K0.29%US$708KSep 30, 2026
Atom Investors LP517K0.29%US$698KSep 30, 2026
Schwab457K0.25%US$617KSep 30, 2026
Simplify Asset Management Inc.434K0.24%US$586KSep 30, 2026
Susquehanna427K0.24%US$576KSep 30, 2026
Ikarian Capital, LLC400K0.22%US$540KSep 30, 2026
BNY368K0.21%US$497KSep 30, 2026
Balyasny Asset Management L.P.358K0.20%US$483KSep 30, 2026
XTX Topco Ltd347K0.19%US$468KSep 30, 2026
Boothbay Fund Management, LLC324K0.18%US$437KSep 30, 2026
ACT Capital Partners, L.P.308K0.17%US$415KSep 30, 2026
Voleon Capital Management LP274K0.15%US$370KSep 30, 2026
Seven Fleet Capital Management LP272K0.15%US$367KSep 30, 2026
American Century206K0.11%US$278KSep 30, 2026
Rhumbline Advisers172K0.10%US$233KSep 30, 2026

This page holds 50 of 113 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
iShares Russell 2000 ETF3.73M2.1%US$7.79MJun 30, 2026
Federated Hermes Kaufmann Small Cap Fund3.14M1.7%US$5.94MJul 31, 2026
Franklin Biotechnology Discovery Fund2.12M1.2%US$4.02MJul 31, 2026
Vanguard Extended Market Index Fund1.72M0.96%US$3.6MJun 30, 2026
Fidelity Small Cap Index Fund1.61M0.90%US$3.05MJul 31, 2026
iShares Russell 2000 Value ETF1.12M0.62%US$2.34MJun 30, 2026
Nuveen Equity Index Fund773K0.43%US$1.47MJul 31, 2026
Fidelity Extended Market Index Fund667K0.37%US$1.41MMay 31, 2026
iShares Micro-Cap ETF496K0.28%US$1.04MJun 30, 2026
Simplify Propel Opportunities ETF451K0.25%US$942KJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Core S&P Total U.S. Stock Market ETF381K0.21%US$796KJun 30, 2026
Schwab Small-Cap Index Fund359K0.20%US$680KJul 31, 2026
Master Small Cap Index Series276K0.15%US$577KJun 30, 2026
Fidelity Total Market Index Fund269K0.15%US$571KMay 31, 2026
iShares Russell 2000 Growth ETF246K0.14%US$515KJun 30, 2026
Nuveen Small Cap Blend Index Fund196K0.11%US$372KJul 31, 2026
Fidelity Series Total Market Index Fund196K0.11%US$416KMay 31, 2026
Fidelity Small Cap Value Index Fund170K0.09%US$355KJun 30, 2026
EQ/2000 Managed Volatility Portfolio160K0.09%US$333KJun 30, 2026
LVIP State Street Small-Cap Index Fund109K0.06%US$227KJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund102K0.06%US$193KJul 31, 2026
Fidelity Nasdaq Composite Index Fund99,6840.06%US$211KMay 31, 2026
Tiff Multi-Asset Fund84,9450.05%US$178KJun 30, 2026
Avantis U.S. Small Cap Equity ETF80,4460.04%US$171KMay 31, 2026
Small Cap Index Fund76,3930.04%US$160KJun 30, 2026
Schwab Total Stock Market Index Fund76,0000.04%US$144KJul 31, 2026
Global X Russell 2000 ETF70,2120.04%US$133KJul 31, 2026
MetLife Russell 2000 Index Portfolio49,8210.03%US$104KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio47,4000.03%US$99,066Jun 30, 2026
NVIT GS Small Cap Equity Insights Fund45,2860.03%US$94,648Jun 30, 2026
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund43,0550.02%US$89,985Jun 30, 2026
Small-Cap Index Portfolio42,3190.02%US$88,447Jun 30, 2026
1290 VT Micro Cap Portfolio33,3260.02%US$69,651Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio32,8290.02%US$68,613Jun 30, 2026
Multi-Manager U.S. Small Cap Equity Fund32,7960.02%US$65,592Apr 30, 2026
NVIT Small Cap Index Fund32,7560.02%US$68,460Jun 30, 2026
Small Cap Index Trust30,6350.02%US$64,027Jun 30, 2026
EQ/AB Small Cap Growth Portfolio26,0200.01%US$54,382Jun 30, 2026
EQ/Small Company Index Portfolio26,0200.01%US$54,382Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund25,8510.01%US$48,988Jul 31, 2026
Fidelity Small Cap Growth Index Fund24,8950.01%US$52,031Jun 30, 2026
DWS Small Cap Index VIP23,1500.01%US$48,384Jun 30, 2026
T. Rowe Price Small-Cap Index Fund22,2540.01%US$46,511Jun 30, 2026
BlackRock Small Cap Index V.I. Fund19,9640.01%US$41,725Jun 30, 2026
Victory Extended Market Index Fund19,7570.01%US$37,440Jul 31, 2026
1290 VT Small Cap Value Portfolio18,7750.01%US$39,240Jun 30, 2026
Voya RussellTM Small Cap Index Portfolio17,869<0.01%US$37,346Jun 30, 2026
SA Small Cap Index Portfolio17,284<0.01%US$32,753Jul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio13,395<0.01%US$27,996Jun 30, 2026
Nationwide Small Cap Index Fund13,052<0.01%US$24,734Jul 31, 2026

This page holds 50 of 73 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Baltera Robert Jr.
Director
Buy50,000USD 1.01US$50,285Nov 17, 2026
Williams Donald Allen
Director
Buy10,000USD 1.46US$14,600Oct 2, 2026
Williams Donald Allen
Director
Buy10,000USD 1.42US$14,200Oct 1, 2026
Baltera Robert Jr.
Director
Buy25,000USD 1.96US$49,000Jul 9, 2026
Baltera Robert Jr.
Director
Buy20,000USD 1.99US$39,800Jul 8, 2026
Finley John David
Director, Officer: CEO, CFO
Sale146,798USD 2.07US$304KJul 7, 2026
Jones Mitchell Lawrence
Officer: Chief Medical Officer
Sale51,880USD 2.05US$106KJul 7, 2026
Baltera Robert Jr.
Director
Buy30,000USD 2.03US$60,900Jul 7, 2026
Baltera Robert Jr.
Director
Buy20,000USD 2.05US$41,000Jul 6, 2026
Baltera Robert Jr.
Director
Buy10,000USD 1.98US$19,800Jul 2, 2026
All 11 trades
TradeTradeSharesPriceValueDate
Baltera Robert Jr.
Director
Buy20,000USD 1.98US$39,600Jul 1, 2026

Big stakes

StakeStakeSharesDateFiling
Janus Henderson Group PLC9.99%14.9MNov 28, 2025Schedule 13G
Armistice Capital, LLC9.99%472KMar 31, 2025Schedule 13G
Ra Capital Management, L.P.9.90%20.9MSep 30, 2026Schedule 13G
Soleus Capital Master Fund, L.P.8.60%15MSep 30, 2026Schedule 13G
Ameriprise Financial Inc8.40%14.6MSep 30, 2026Schedule 13G
Perceptive Advisors LLC7.90%14.1MMar 31, 2026Schedule 13G
Octagon Capital Advisors LP6.40%9.57MDec 31, 2025Schedule 13G
BlackRock, Inc.6.00%10.4MJun 30, 2026Schedule 13G
Franklin Resources Inc6.00%9.16MDec 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Catherine Angell Sohn
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Altimmune, Inc. (Director · Since at least Mar 23, 2023); Axcella Health Inc (Director · Aug 21, 2019 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Lifecore Biomedical, Inc. (Director · Nov 13, 2012 – Jun 4, 2022 · Past); Jazz Pharmaceuticals plc (Director · Jul 27, 2012 – Aug 11, 2023 · Past)
Director · Jan 13, 2014 – Jul 1, 2015 · Past
David J Mazzo
Other companies: Lisata Therapeutics, Inc. (President & CEO, Director · Since at least Jan 5, 2015); Tobira Therapeutics Inc (Chief Executive Officer, Director · Aug 21, 2013 – Jan 1, 2014 · Past); EyePoint, Inc. (Director · Jul 13, 2007 – Feb 28, 2020 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – Feb 12, 2014 · Past)
Director · Jun 17, 2019 – Apr 1, 2021 · Past
Mary Ann Gray
Other companies: BioAtla, Inc. (Director · Since at least Jun 16, 2022); Keros Therapeutics, Inc. (Director · Since at least Jun 1, 2022); Compass Therapeutics, Inc. (Director · Since at least Apr 26, 2022); RAPT Therapeutics Inc (Director · Since at least Mar 31, 2022)
Director · Jun 11, 2023 – Nov 21, 2023 · Past
Robert Baltera Jr
Other companies: Imago Biosciences Inc (Director · Jul 15, 2021 – Jan 11, 2023 · Past); Frazier Lifesciences Acquisition Corp (Director · Dec 8, 2020 – Nov 22, 2022 · Past); Xencor, Inc. (Director · Dec 2, 2013 – Jun 23, 2016 · Past); VivoSim Labs, Inc. (Director · Mar 13, 2012 – Jul 26, 2018 · Past)
Director · Since at least Jun 10, 2026
James R. Neal
Other companies: Akari Therapeutics PLC (Director · Since at least Nov 14, 2024); Processa Pharmaceuticals, Inc. (Director · Since at least Jul 19, 2022); Monterey Bio Acquisition Corp (Director · Sep 30, 2021 – Sep 30, 2021 · Past)
Director · Apr 27, 2021 – Feb 9, 2024 · Past
Donald A. Williams
Other companies: Akari Therapeutics PLC (Director · Jan 1, 2024 – Jun 28, 2024 · Past)
Director · Since at least Jun 10, 2026
Jones Jonathan Brian Lloyd
Other companies: Juniper Pharmaceuticals Inc (Vice President & CFO · Jan 15, 2013 – May 5, 2014 · Past)
Chief Financial Officer · May 18, 2015 – Mar 24, 2017 · Past
William Clyde Oldaker
Other companies: WashingtonFirst Bankshares Inc (Director · Jan 1, 2018 – Jan 1, 2018 · Past)
Director · Jul 2, 2018 – Jul 1, 2019 · Past
Adarsh PatelHead of Chemistry, Manufacturing and Controls (CMC) · Since at least Nov 4, 2026
Binxian WeiDirector · Since at least Jun 10, 2026
All 29 people
PersonSeat
Daniel J. LarkinsHead of Global Regulatory Affairs · Since at least Nov 4, 2026
Dawn LouroHead of Clinical Operations · Since at least Nov 4, 2026
Emil ChuangDirector · Since at least Jul 7, 2025
James IzanecHead of Clinical Development · Since at least Sep 28, 2026
JD FinleyChief Executive Officer and Director · Since at least Oct 28, 2026
Joerg HeyerHead of Translational Science and Medicine · Since at least May 1, 2025
John David FinleyCEO CFO, Director · Since at least Apr 29, 2022
Jordan ZwickDirector · Since at least Jun 10, 2026
Julien E. CapersSee Remarks · Since at least Oct 19, 2026
Kenneth C CarterExecutive Chairman, Director · Dec 12, 2018 – Dec 12, 2018 · Past
Margery B FischbeinDirector · May 7, 2024 – Jul 11, 2024 · Past
Michael John DawsonChief Medical Officer · Apr 27, 2021 – Mar 29, 2022 · Past
Mitchell Lawrence JonesSee Remarks · Since at least Sep 4, 2025
Mitch JonesPresident and Chief Medical Officer · Since at least Oct 28, 2026
Ramesh DonthamsettyHead of IR and Corporate Strategy · Since at least Nov 4, 2026
Robert BalteraDirector · Since at least Jul 10, 2026
Robert J TrenschelDirector · Apr 27, 2021 – Feb 8, 2024 · Past
Ryker WillieHead of Finance and Corporate Controller · Since at least Nov 4, 2026
Stephanie DiazDirector · Apr 27, 2021 – Feb 8, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Palisade Bio, Inc.